Aerosol therapy for the treatment of tuberculosis and other pulmonary infections
is growing due to the accessibility of local targeting, the complexities of treatment
by conventional routes and the impressive advancement of inhalation technology.
The understanding of the molecular and cellular mechanisms, local immunology and pathophysiology
of tuberculosis dictates the strategies for delivering selected drugs and vaccines to the site of infection
for successful outcomes in this important therapeutic endeavor. Difficulties may be experienced with respect
to delivery of two or three potent but poorly bioavailable drugs, barriers to the treatment due to co-infection,
impact of pathophysiology factors on the fate of inhaled medicines or multidrug resistance. Due to the long duration
of therapy and drug combination required, treating TB by inhalation could teach how to translate the therapy outcomes
to other infections prevalent in cystic fibrosis, bronchiectasis or COPD.
This meeting focuses on tuberculosis and intends from TB therapy to translate products,
technologies and procedures for efficiently treating the pulmonary infective diseases.